论文部分内容阅读
目前在光动力学疗法中用于诊断和治疗恶性肿瘤的光敏剂血卟啉,尽管对肿瘤组织有一定的亲和力,但因对肿瘤细胞的选择性不够强,对肿瘤周围及其它正常组织也有损伤。因此,更优良的光敏剂的研制急待解决。将血卟啉(HP)与抗肿瘤单克隆抗体相连制备成“免疫光敏剂”,就可借助单克隆抗体
The photosensitizer hematoporphyrin, which is currently used for the diagnosis and treatment of malignant tumors in photodynamic therapy, has a certain affinity for tumor tissues, but it is also insensitive to tumors and other normal tissues due to insufficient selectivity for tumor cells. . Therefore, the development of more excellent photosensitizers has yet to be resolved. Combining hematoporphyrin (HP) with an anti-tumor monoclonal antibody to prepare an “immunity photosensitizer” that can be used with monoclonal antibodies